Interleukin-6-634C > G polymorphism in hypertensive patients with and without left ventricular hypertrophy
Department of Cardiology, Fourth People's Hospital of Wuxi, Wuxi 214062, P.R. China.Molecular Medicine Reports (Impact Factor: 1.55). 03/2011; 4(2):283-9. DOI: 10.3892/mmr.2011.411
There is an accumulating body of evidence indicating that inflammation plays a pivotal role in the pathogenesis of cardiovascular disease. Interleukin-6 (IL-6) is a pleiotropic cytokine secreted by many cells of the immune system, cardiovascular components and adipose tissue, and functions as a mediator of inflammatory response with both pro- and anti-inflammatory properties. Circulating levels of IL-6 differ greatly between individuals due to both genetic and environmental factors. The IL-6 -634C>G polymorphism is common in eastern Asian populations. The aim of the present study was to investigate the association of this polymorphism with essential hypertension (EH) and left ventricular hypertrophy (LVH) in 440 subjects (246 EH patients and 194 controls) from a Han Chinese population. In this study, IL-6 -634C>G genotypes were identified by polymerase chain reaction and restriction digestion in all study participants, and left ventricular mass was assessed by 2-mode echocardiography in 178 untreated EH patients. There was no significant difference in either genotype distribution (p=0.9528) or allele frequency (p=0.7775) between the EH and control groups. In addition, the -634C>G polymorphism had no effect on blood pressure in either the controls or the untreated EH patients. No significant differences in genotype distribution (p=0.7998) or allele frequency distribution (p=0.5468) were found between EH patients with and without LVH. Moreover, the echocardiographic parameters were not statistically different between the CC and CG+GG genotypes. These findings suggest that there is no association of the IL-6 -634C>G polymorphism and EH with LVH in EH patients.
- [Show abstract] [Hide abstract]
ABSTRACT: Atrial fibrillation (AF) not only is an independent risk factor for death but also confers significant risk of morbidity from stroke associated with left atrial thrombus. The association of interleukin 6 (IL-6) polymorphism with thrombus in AF has not been investigated before. We carried out a case-control study in Han Chinese. The IL-6 -634C/G genotypes of 31 patients with thrombus and 45 patients without thrombus were detected by polymerase chain reaction and restriction fragment length polymorphism. The frequencies of the IL-6 genotypes (CC, CG, and GG) were 29.03%, 54.54%, and 16.13% for the patients with thrombus, and 55.56%, 40.00%, and 4.44% for the patients without thrombus, respectively (P = .0391). Compared with the CC genotype, the G allele carriers (CG + GG) had a 2.79-fold increased risk of thrombus or severe spontaneous echocontrast (SEC). These results suggest that IL-6 -634C/G polymorphism is associated with thrombus and severe SEC, and the G allele is an independent risk for thrombus and severe SEC in Han Chinese patients with AF.Clinical and Applied Thrombosis/Hemostasis 08/2012; 19(6). DOI:10.1177/1076029612457706 · 2.39 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: There is an accumulating body of evidence indicating a strong association between inflammation and the pathogenesis of atrial fibrillation (AF). Interleukin-6 (IL-6) is a pleiotropic cytokine, functions as a mediator of inflammatory response, and has both proinflammatory and anti-inflammatory properties. The aim of the present study was to investigate the association of the -634C/G polymorphism of the IL-6 gene with AF in elderly Han Chinese patients with essential hypertension (EH). A total of 169 elderly patients with EH were eligible for this study. Patients with AF (n=75) were allocated to the AF group, and 94 subjects without AF to the control group. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique was used to assess the genotype frequencies. The distribution of the IL-6 -634C/G genotypes (CC, CG, and GG) was 67.02%, 30.85%, and 2.13% in the controls, and 50.67%, 40.00%, and 9.33% in AF subjects, respectively (P=0.0312). The frequency of the G allele in the AF group was significantly higher than that in the control group (29.33% vs. 17.55%, P=0.0103). Compared with the CC and CG genotypes, the GG homozygote had a 4.7353-fold increased risk of AF [95% confidence interval (CI)=0.9537-23.5116, P=0.0382]. These findings suggest that the IL-6 -634C/G polymorphism is associated with AF, and the G allele has increased risk of AF in elderly Han Chinese patients with EH.Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research 08/2012; 32(11)(11). DOI:10.1089/jir.2012.0033 · 2.00 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: There is an accumulating body of evidence indicating association between inflammation and the pathogenesis of coronary vasospastic angina (CVA). Interleukin-6 (IL-6) is a pleiotropic cytokine, functions as a mediator of inflammatory response and has both pro-inflammatory and anti-inflammatory properties. The aim of the present study is to investigate the association of -634C/G polymorphism of IL-6 gene with CVA in Han Chinese. A total of 27 CVA patients and 232 healthy controls were eligible for this study. The PCR-based restriction fragment length polymorphism (PCR-RFLP) technique was used to assess the genotypes frequencies. The distribution of the IL-6 -634C/G genotypes (CC, CG, and GG) was 59.48%, 37.07%, and 3.45% in the controls, and 37.04%, 48.15%, and 14.81% in CVA group, respectively (P = 0.0080). The frequency of the G allele in the CVA group was significantly higher than that in the control group (38.89% vs 21.98%, P = 0.0057). Compared with the wild type CC, the G allele carriers (CG + GG genotypes) had increased risk of CVA in both unadjusted and adjusted analyses. These findings suggest that IL-6 -634C/G polymorphism is associated with CVA and the G allele is an independent risk for CVA in Han Chinese.International Journal of Clinical and Experimental Medicine 09/2014; 7(9):2858-64. · 1.28 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.